This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

ImmunoGen, Inc. Announces Presentation Of New IMGN901 Clinical Data

Activity Noted

Three of the 13 patients with SCLC enrolled had chemotherapy-naïve disease. Two of these three patients had an objective response (partial response or PR) by RECIST criteria to treatment with IMGN901 plus E/C.

All of the 10 patients with previously treated SCLC had received prior platinum-based therapy, and seven of these patients had platinum-resistant/refractory disease. Four of these ten patients had a PR, including two of the patients with platinum-resistant/refractory disease.

Among all of the 33 patients enrolled, ten had an objective response, and 24 (72.7%) had disease control (objective response or stable disease).

ImmunoGen’s NORTH Trial

The 120-patient NORTH trial is designed to evaluate the efficacy and safety of IMGN901 for first-line treatment of extensive disease SCLC. All patients enrolled are provided with up to six cycles of C/E. Two-thirds of the patients enrolled are randomized to also receive IMGN901. These patients can elect to remain on IMGN901, as monotherapy, after completion of the C/E cycles if benefiting from treatment. The trial is designed to compare the findings in the IMGN901-including treatment arm to historic controls, with the control arm serving to verify consistency with historical results.

The NORTH trial utilizes a Simon Two-Stage Design: once 59 patients have been enrolled across the two study arms, those two cohorts of patients will be followed for an interim analysis of progression-free survival (PFS) at 6 months. The interim analysis will focus on whether the IMGN901-including treatment arm met pre-defined clinical benefit hurdles. Success on this interim analysis will serve as a basis for certain development decisions by the Company.

The primary endpoint of the NORTH trial is PFS. Secondary endpoints include PFS at 6 months, overall survival at 12 months, time to progression, overall survival, and overall response rate.

About IMGN901

IMGN901 is designed to target and kill CD56+ cancer cells. This TAP compound is wholly owned by ImmunoGen and consists of the Company’s CD56-targeting antibody with its DM1 cancer-cell killing agent attached using one of its engineered linkers. IMGN901 has been granted orphan drug designation for SCLC in the US and Europe.

2 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,712.66 +34.43 0.19%
S&P 500 2,061.02 +4.87 0.24%
NASDAQ 4,891.2190 +27.8570 0.57%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs